ClinicalTrials.gg
CompletedNCT02659397Updated Mar 29, 2019

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

A Phase 2 interventional study of ETC-1002 and Atorvastatin in Hyperlipidemia, sponsored by Esperion Therapeutics, Inc.. Completed at 19 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-03-29.

Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 338 studies in Hyperlipidemias with a site in United States — 30 open to participants now, 45 under way, 10 of them phase 3. Hyperlipidemias · United States.

Enrollment
189th of 306
68 · median 120
Started
2015
with 17 others
Phase 2
43 of 338
2 open now
Registered
212th of 338
by date
Lead sponsor
8 of 338
Esperion Therapeutics, Inc.

Among the 338 studies in Hyperlipidemias with a site in United States, this one is the 189th largest by enrollment of the 306 interventional ones that give a count, is one of 18 that started in 2015, is one of 43 in phase 2, and was the 212th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

30 of the 338 studies in Hyperlipidemias with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 338 studies in Hyperlipidemias with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to measure the amount of atorvastatin and ETC-1002 in the blood, to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in blood and urine, and to see how ETC-1002 is tolerated in the body compared to placebo when added to stable atorvastatin 80 mg background therapy in statin-treated patients.

03

Conditions studied

  • Hyperlipidemia

Keywords

  • LDL-cholesterol
  • Hypercholesterolemia
  • ETC-1002
  • Adenosine triphosphate citrate lyase
  • Atorvastatin
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Taking daily stable statin doses for at least 4 weeks prior to screening visit.
  • LDL-C between 100-220 mg/dL for patients taking daily high-intensity statin (for 4 weeks prior to switching to sponsor -provided atorvastatin 80 mg/day and stopping all other lipid-regulating drugs and supplements) at the screening visit; or,
  • LDL-C between 115-220 mg/dL for patients taking moderate- or low-intensity statin (for 4 weeks prior to switching to sponsor -provided atorvastatin 80 mg/day and stopping all other lipid-regulating drugs and supplements) at the screening visit.
  • Must be willing to discontinue other lipid-regulating therapies during the study

Exclusion criteria

Exclusion Criteria:

  • History of acute significant cardiovascular disease.
  • Current cardiovascular disease.
  • History of inability to tolerate any statin at any dose due to muscle-related pain or weakness.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    ETC-1002 + Atorvastatin

    ETC-1002 180 mg treatment, oral once daily added-on to Atorvastatin 80 mg once daily

    Drug: ETC-1002 · Drug: Atorvastatin

  • Placebo comparator
    Placebo + Atorvastatin

    Placebo treatment, oral once daily added-on to Atorvastatin 80 mg once daily

    Drug: Atorvastatin · Drug: Placebo

Interventions

  • Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)

    Also known as: bempedoic acid

  • Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)

  • DrugPlacebo

    Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration (Cmax) pharmacokinetics of atorvastatin and its active metabolites

    Fold change in Cmax from prior-to to following 2 week treatment with ETC-1002

    Time frame: 2 weeks

  2. 24-hour area under the curve (AUC) pharmacokinetics of atorvastatin and its active metabolites

    Fold change in AUC from prior-to to following 2 week treatment with ETC-1002

    Time frame: 2 weeks

  3. Percent change in LDL-cholesterol

    Percent Change from baseline to 4 week treatment, incremental lowering of LDL-C

    Time frame: 4 weeks

Secondary outcomes

  1. Percent change in hsCRP

    Percent change from baseline to following 4 week treatment with ETC-1002

    Time frame: 4 weeks

  2. Percent change in total cholesterol

    Percent change from baseline to following 4 week treatment with ETC-1002

    Time frame: 4 weeks

  3. Percent change in non-HDL-cholesterol

    Percent change from baseline to following 4 week treatment with ETC-1002

    Time frame: 4 weeks

  4. Percent change in apolipoprotein B

    Percent change from baseline to following 4 week treatment with ETC-1002

    Time frame: 4 weeks

  5. 24-hour post dose plasma concentration pharmacokinetics of ETC-1002 and its active metabolite

    Fold change in trough exposure from prior-to to following 2 week treatment with ETC-1002

    Time frame: 2 weeks

07

Study locations

19 sites
  • Anaheim, California 92801, United States
  • Los Angeles, California 90057, United States
  • Northridge, California 91324, United States
  • Clearwater, Florida 33765, United States
  • Jacksonville, Florida 32216, United States
  • Miami, Florida 33126, United States
  • Port Orange, Florida 32127, United States
  • Boise, Idaho 83642, United States
  • Chicago, Illinois 60607, United States
  • Springfield, Illinois 62711, United States
  • Louisville, Kentucky 40213, United States
  • Berlin, New Jersey 08009, United States
  • Rapid City, South Dakota 57701, United States
  • Carrollton, Texas 75006, United States
  • West Jordan, Utah 84088, United States
  • Arlington, Virginia 22203, United States
  • Lynchburg, Virginia 24501, United States
  • Richmond, Virginia 23294, United States
  • Renton, Washington 98057, United States
08

References and documents

Publications

  • Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, Newton RS. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015 May-Jun;9(3):295-304. doi: 10.1016/j.jacl.2015.03.003. Epub 2015 Mar 19. PubMed 26073387 ↗
  • Nikolic D, Mikhailidis DP, Davidson MH, Rizzo M, Banach M. ETC-1002: a future option for lipid disorders? Atherosclerosis. 2014 Dec;237(2):705-10. doi: 10.1016/j.atherosclerosis.2014.10.099. Epub 2014 Oct 31. PubMed 25463109 ↗
  • Filippov S, Pinkosky SL, Newton RS. LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase. Curr Opin Lipidol. 2014 Aug;25(4):309-15. doi: 10.1097/MOL.0000000000000091. PubMed 24978142 ↗
  • Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, Milad MA, McBride SJ, Newton RS. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):676-83. doi: 10.1161/ATVBAHA.113.302677. Epub 2014 Jan 2. PubMed 24385236 ↗
  • Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, Newton RS. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24;62(13):1154-62. doi: 10.1016/j.jacc.2013.05.050. Epub 2013 Jun 13. PubMed 23770179 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2016
First posted
Jan 20, 2016
Start
Dec 2015
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Results delay requested
Dec 14, 2016
Last update
Mar 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02659397
Responsible party
Sponsor
First posted
Jan 20, 2016
Start date
Dec 2015
Primary completion
Jul 2016
Completion
Jul 2016
Last update
Mar 29, 2019

Study contacts

Mary McGowan, MD
study director · Esperion Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion